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Background: Human immunodeficiency virus (HIV) seropositivity may be associated with
higher risk of local recurrence and poor survival in multiple malignancies. However, long-
term disease control in HIV-positive patients with head and neck cancer (HNC) is not well
described. The purpose of this study is to review the disease-related outcomes of HIV-
positive patients who underwent radiotherapy (RT) or chemoradiotherapy (CRT) at our
institution.
Methods: We retrospectively reviewed 24 HIV-positive patients who underwent RT for
HNC between 2004 and 2013. Patient characteristics, treatment details, and outcomes
were collected. Overall survival (OS) and local recurrence-free survival (LRFS) were
investigated. Kaplan–Meier estimated survival was calculated.
Results: Median follow-up was 21 months. All patients were treated with curative intent.
Eighty-three percent had stage III–IV. Primary sites of disease included oropharynx (n=12),
larynx (n=6), oral cavity (n=2), unknown primary (n=2), nasal cavity (n=1), and paranasal
sinuses (n=1). Four patients (17%) had definitive RT alone and nine had definitive CRT
(38%; eight cisplatin and one cetuximab). Eleven (46%) were treated in the adjuvant setting
after surgical resection; six with RT alone and five with concurrent cisplatin. Eight patients
had acute Grade 3 toxicity with no acute Grade 4 or 5 toxicities. Fifteen patients (63%)
were alive and disease-free. Two- and 5-year OS was 67 and 59%, respectively. LRFS at
2-years was 82%. Median OS was 83 months.
Conclusion: In this cohort, HIV-positive patients treated aggressively with curative intent
had excellent OS and local control following RT or CRT for HNC compared to historical con-
trols. Treatment was relatively well tolerated. This group of patients should be managed
aggressively with intent to cure.
Keywords: human immunodeficiency virus, head and neck cancer, radiotherapy, squamous cell carcinoma,
oropharynx
INTRODUCTION
In the highly active anti-retroviral therapy (HAART) era, human
immunodeficiency virus (HIV)-positive patients are living longer
and are at higher risk for developing non-AIDS-defining malig-
nancies (1–3). The incidence of head and neck cancer (HNC)
in particular, has increased markedly since the widespread use
of HAART (3–6). Despite becoming a more common problem,
the optimal management of HNC in HIV-positive patients is
unknown because of a paucity of data.
In HIV-positive patients with anal squamous cell carcinoma
(SCC), some have argued against aggressive therapy in patients
with advanced disease, citing concerns regarding increased toxi-
city after chemoradiation (CRT) (7, 8). The combined modality
treatment of HNC with concurrent CRT in both the definitive
and adjuvant setting results in improved disease outcomes at
the cost of added toxicity (9–12). However, the magnitude of
increased toxicity in HIV-positive patients is not well described.
Some reports suggest that the acute toxicity of radiotherapy (RT)
or CRT in HIV-positive HNC patients is comparable to that of
HIV-negative patients (13–15). However, data from Mourad et al.
suggest that RT is less tolerated among HIV-positive patients (16),
possibly narrowing the therapeutic window in this fragile patient
population.
Data on disease-related outcomes of HIV-positive patients
with HNC are lacking. However, this information is essential for
oncologists to effectively weigh the certainty of treatment tox-
icity against the potential benefit of aggressive treatment when
making management decisions in this patient population. Further-
more, a better understanding of disease control and survival rates
aids in counseling patients on reasonable treatment expectations.
Here, we review our single institution experience treating HNC in
HIV-positive patients over a 10-year period and describe clinical
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outcomes. Secondary objectives include reporting acute toxicity,
patterns of failure, and other factors, which may affect prognosis
in HIV-positive HNC patients.
MATERIALS AND METHODS
PATIENTS
Approval of the Institutional Review Board was obtained for this
retrospective study. All patients who received radiation therapy to
the head and neck in our department between 2004 and 2014 were
reviewed. Our radiation oncology department services patients
from both a hospital that mainly accepts patients with private
insurance and a public, community-based hospital, which is oblig-
ated to treat prisoners, underinsured, and uninsured patients.
Patients from both institutions were included in this analysis.
HIV-positive patients with cancer of the aerodigestive tract were
identified. Two of 13 patients from our previous report on acute
toxicity were excluded (squamous cell cancer of the skin and
parotid hyperplasia) from this analysis (13). The remaining 11
patients and 13 additional patients were included and evaluated
for long-term disease-related outcomes. Patient and treatment-
related data that were examined included age, gender, histologic
diagnosis, primary disease site, stage of disease, human papil-
lomavirus (HPV) status, HAART therapy, RT technique [three-
dimensional conformal radiotherapy (3D-CRT) or intensity mod-
ulated radiotherapy (IMRT)], total RT dose, duration of RT, and
the presence of concurrent chemotherapy. HIV-related informa-
tion examined included pre-treatment CD4+ lymphocyte count
and viral load. Patient toxicity data were manually garnered from
the radiation and medical oncology treatment charts. All initial
consultation, weekly radiation on-treatment, medical oncology
on-treatment, and follow-up notes were examined. The electronic
medical record of the referring hospital system was systematically
queried in addition to the paper charts for every patient.
TREATMENT AND FOLLOW-UP
All treatments were delivered with megavoltage photon or elec-
tron beams. In patients receiving concurrent chemotherapy, cis-
platin 100 mg/m2 was given every 3 weeks in all but one patient,
who received cetuximab 400 mg/m2 loading dose followed by
250 mg/m2 weekly for the duration of radiation therapy. Patients
were evaluated by a radiation oncologist on a weekly basis during
RT, then monthly in multidisciplinary clinic with an otolaryn-
gologist, radiation oncologist, and medical oncologist following
RT completion for 3 months, then every 3 months. Acute and late
toxicity was assessed as well as any treatment-related complica-
tions. Treatment outcomes that were examined included presence
of local recurrence, distant metastasis, and death. HIV specific
follow-up was at the discretion of the treating infectious disease
specialist.
STATISTICS
Chi-square test was used to compare frequencies and t -test was
used to compare means. Overall survival (OS) was defined as
the duration from the start of RT to most recent follow-up or
death. Local recurrence-free survival (LRFS) was defined as time
from start of RT to most recent follow-up, tumor recurrence
at the primary site or death. Survival estimates were calculated
according to the Kaplan–Meier method. All statistical analy-
ses were performed using SPSS version 20 (SPSS Inc., Chicago,
IL, USA).
RESULTS
PATIENT CHARACTERISTICS
Twenty-four HIV-positive patients underwent RT for HNC of the
aerodigestive tract. Median age was 53 (range, 32–67); 4 patients
were women, 20 were men. Twenty-three patients had SCC, one
patient had sarcomatoid SCC (Table 1). Primary disease sites
included oropharynx (n= 12), larynx (n= 6), oral cavity (n= 2),
unknown primary (n= 2), nasal cavity (n= 1), and paranasal
sinuses (n= 1). Three patients (13%) had stage II disease, 5 (21%)
had stage III, 14 (58%) had IVA, and 2 (8%) had IVB. Six-
teen patients reported smoking ever; four patients reported ≥10
pack-years smoking history.
SURVIVAL
At a median follow-up of 21 months, 16 patients (67%) were
alive and 15 (63%) were alive and free of disease. Projected 2
Table 1 | Patient and disease characteristics.
Characteristic Total patients (%)
Gender
Male 20 (83)
Female 4 (17)
Histology
SCC 23 (96)
Sarcomatoid SCC 1 (4)
Primary site
Oropharynx 12 (50)
Larynx 6 (25)
Oral cavity 2 (8)
Unknown primary 2 (8)
Nasal cavity 1 (4)
Paranasal sinuses 1 (4)
T Stage
Tx 1 (4)
T0 2 (8)
T1 3 (13)
T2 7 (29)
T3 5 (21)
T4 6 (25)
N Stage
N0 8 (33)
N1 4 (17)
N2 10 (42)
N3 2 (8)
AJCC seventh edition stage group
II 3 (13)
III 5 (21)
IVA 14 (58)
IVB 2 (8)
SCC, squamous cell carcinoma; AJCC, American Joint Committee on Cancer.
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FIGURE 1 | Overall survival among human immunodeficiency
virus-positive patients undergoing radiotherapy for head and neck
cancer.
FIGURE 2 | Local recurrence-free survival among human
immunodeficiency virus-positive patients undergoing radiotherapy for
head and neck cancer.
and 5-year OS was 67 and 59%, respectively (Figure 1). Median
OS was 83 months (95% CI 9.4–156 months). Causes of death
include widespread metastases (n= 4), progression of primary
(n= 2), sepsis during chemotherapy for second primary malig-
nancy (lung) (n= 1), and unknown (n= 1). Of note, no patients
died of complications from acquired immunodeficiency. Projected
2-year LRFS was 82% (Figure 2), median LRFS was not reached.
Of the patients who experienced local failure, primary sites of
disease included base of tongue (n= 3) and retromolar trigone
(n= 1).
HIV-RELATED PARAMETERS
Data on HAART were available for 22 patients, 19 (86%) of which
were on HAART at the time of consultation. All 19 patients on
HAART continued therapy concurrently with RT. Twelve patients
were taking protease inhibitors concurrently with RT. CD4+ lym-
phocyte counts were available for 12 patients. Median CD4+ cell
count was 261 cells/µL (range 71–858 cells/µL). HIV viral load was
available for 12 patients. Ten patients had an undetectable viral
load (<50 copies/mL), one had a viral load 687 copies/mL, and
one patient not on HAART had viral load 46,600 copies/mL. HPV
status was available for three patients, two of whom were HPV-
positive. There was no significant difference in rates of death, local
recurrence, or distance metastases among patients taking HAART
medications. There was also no significant difference in the rate
of death, local recurrence, or metastases among patients taking
protease inhibitors.
RADIOTHERAPY DETAILS
Radiotherapy was delivered by 3D-CRT for 15 patients (63%) and
IMRT for 9 (37%). Four patients (17%) had definitive RT alone
and nine CRT (38%; eight cisplatin and one cetuximab). Eleven
(46%) were treated in the adjuvant setting after surgical resection,
six with RT alone and five with concurrent cisplatin. Median RT
dose for patients undergoing definitive treatment was 70 Gy (range
35–70.4 Gy) and median RT dose for patients undergoing post-
operative treatment was 66 Gy (range 54–70 Gy). Three patients
(13%) terminated treatment prematurely. One patient had pro-
gression of disease and treatment was terminated at 35 Gy. The
patient expired 12 days later. Two patients stopped coming in for
treatment mid-course and were lost to follow-up despite multiple
phone calls and sending a certified letter. All patients were treated
with conventional fractionation daily, 5 days a week. Two patients
received 1.8 Gy per fraction, all others received 2 Gy per fraction.
Median RT course duration was 53 days (range 21–71 days).
HEMATOLOGIC DETAILS
The median pre-treatment white blood cell count, absolute
neutrophil count (ANC), hemoglobin level, and platelets were
6,100 cells/µL, 3,700 cells/µL, 11.1 g/dL, and 240,000 cells/µL,
respectively. The median nadir of the white blood cell count, ANC,
hemoglobin level, and platelets were 2,200 cells/µL, 1,200 cells/µL,
8.9 g/dL, and 145,000 cells/µL, respectively. One patient receiv-
ing chemotherapy and one patient treated definitively with RT
alone required hospitalization for neutropenic fever. The patient
being treated with RT alone had local disease progression and
eventually died of sepsis related to the progressive disease. This
corresponded to an 8% rate of admission for neutropenic fever
in the entire cohort. Eight of 24 patients became neutropenic
(ANC< 1,000 cells/µL) at some point during their treatment,
most of whom were treated with granulocyte colony-stimulating
factor support. Interestingly, three of the patients who became
neutropenic were not receiving chemotherapy.
TOXICITY
Grade 0, 1, and 2 toxicities are displayed in Table 2. There were
no Grade 4 or 5 acute toxicities in this series. Eight patients (33%)
experienced Grade 3 toxicity: three had Grade 3 dermatitis, four
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Table 2 | Acute toxicity: RTOG common toxicity criteria and total
numbers of patients affected.
Acute toxicity Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Dermatitis 1 7 5 3 0
Mucositis 2 3 8 4 0
Fatigue 16 0 1 0 0
Esophagitis 9 3 4 1 0
Nausea 14 1 1 0 0
Anorexia 14 2 1 0 0
Xerostomia 3 7 5 0 0
RTOG, radiation therapy oncology group.
had Grade 3 mucositis, and one had Grade 3 esophagitis (Table 2).
One patient with T4aN2b base of tongue cancer had laryngeal
edema necessitating an extended treatment break, resulting in a
treatment time of 71 days total. Three patients had oropharyn-
geal thrush during RT, which resolved with topical antifungal
treatment. Median weight loss in the entire cohort was 5.9 kg
(range 2.3–13.6 kg). Median weight loss in the patients treated
with or without concurrent chemotherapy were 7.5 and 5.5 kg,
respectively. This corresponded to a weight loss as a percentage of
total body weight 11.2% (range −8 to 30%) in patients receiving
concurrent chemotherapy compared to 7.4% (range 3–19%) in
patients without combined therapy. The only patient that gained
weight during treatment (−8% weight loss) was because of PEG
tube placement after a difficult post-operative course.
There were no significant increases in the frequency of Grade 3
toxicity among patients taking HAART. Severe late RT complica-
tions were rare. One patient had wound dehiscence after adjuvant
RT for T1N2b tonsillar cancer. He did not receive concurrent
chemotherapy and was not on HAART. One patient developed a
tracheoesophageal fistula after adjuvant CRT to for T3N2c supra-
glottic larynx cancer. One patient T1N2a supraglottic larynx can-
cer treated with definitive CRT to 70 Gy was PEG-dependent until
his death in 2010.
DISCUSSION
In our series, HIV-positive patients treated with definitive or adju-
vant RT or CRT for HNC had 67% OS and 82% local control at
a median follow-up of 2 years, comparing favorably with histor-
ical data. In addition, treatment was well-tolerated with limited
acute toxicity and rare late complications. Further, while highly
curable, HNC in HIV-positive patients remains potentially life-
threatening. In our series, three-quarters of all patient deaths were
a result of local or distant progression of disease. These find-
ings provide further evidence to support a curative approach to
HIV-positive patients with HNC.
Historically, advanced HNC has been a difficult disease to man-
age, with morbid treatment and poor long-term disease-related
outcomes. The expected 2-year OS and local control after definitive
CRT for stage III–IV HNC in immunocompetent patients range
from 40 to 75% and 60 to 80%, respectively (11, 17, 18). Results
after surgical resection and adjuvant CRT are similar, with approx-
imately 65–75% survival and 80–85% local control at 2-years (9,
10). Klein et al. published the first report on disease outcomes
among HIV-positive patients (14). While their study is limited by
small sample size (n= 12), they report excellent results with 78%
OS and 92% local control at 3-years. More recently, Mourad et al.
reported 69% locoregional control and 55% OS at 4 years among
73 HIV-positive patients treated with definitive RT (19).
There are several possible explanations for these favorable
results. First, we treated all patients aggressively, with multimodal-
ity treatment where appropriate. Our treatment strategy is not
modified based on HIV status. While each patient is approached
individually, our general practice is CRT for definitive treatment
of stage III/IV HNC and adjuvant CRT for high-risk pathologic
features including positive margins and extracapsular extension.
These strategies were employed in the majority of patients on this
study.
The epidemiology of HNC is changing, and favorable outcomes
in our series may be a reflection of this. In recent years, the inci-
dence of HPV-unrelated HNC has declined while HPV-associated
HNC is on the rise (20). HPV-positive HNC patients have a signif-
icantly better prognosis than HPV-negative patients (21) and high
rates of HPV-positivity in our cohort may contribute to the favor-
able results we observed. Unfortunately, because most patients in
this series were treated before HPV testing became institutional
policy, we were only able to obtain HPV status from pathologic
specimens of three patients. Also, to complicate matters, both
referring hospital’s pathology departments were submerged in Fall
of 2012 due to a weather related catastrophe, making retrospec-
tive HPV analysis of possible stored specimen impossible. There
are, however, other characteristics that suggest that a high-HPV-
positivity rate in this cohort including younger age at diagnosis
(median 53 years), high proportion of oropharyngeal primary site
(50%), and lack of heavy smoking history (17% patients had >10
pack-years).
It is possible that the addition of protease inhibitors concurrent
with RT contributed to improved outcomes. Protease inhibitors
block the Akt signaling pathway and result in synergistic tumor
killing when given concurrently with RT (22). In our series, the
administration of concurrent protease inhibitor with RT did not
result in either worse toxicity or improved disease-related out-
comes. However, this analysis is limited by small patient numbers,
making it difficult to draw meaningful conclusions based on these
data. The impact of protease inhibitors on clinical outcomes
requires further exploration as it may have important implica-
tions for the widespread application of this therapy for tumors of
many disease sites (23).
Acute toxicity in this cohort compares favorably with histor-
ical controls. RT alone typically results in <25% Grade 3 or 4
mucositis in immunocompetent patients. The addition of con-
current chemotherapy increases the risk of Grade 3–4 mucositis to
32–84% (24). Here, we observed 33% had any Grade 3 acute toxic-
ity and 17% had Grade 3 mucositis. We did not report rates of late
toxicity because follow-up notes did not consistently classify toxic-
ity by RTOG Grade. We determined that retrospectively converting
narrative descriptions of late effects from notes to RTOG Grade
was an extrapolation that introduced a high degree of uncertainty
and bias to these data.
Looking forward, HIV-positive HNC patients may be excellent
candidates for molecular targeted therapy. The ongoing RTOG
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1016 study randomizes p16-positive HNC patients with clini-
cal stage T1-2, N2a-3, or T3-4, any N to concurrent accelerated
RT with either cisplatin or cetuximab. This head to head com-
parison will determine whether cetuximab results in equivalent
survival as compared to cisplatin. The results of this trial are highly
anticipated as they may usher in a new era in which chemother-
apy is replaced by molecular targeted agents in HPV-positive
HNC. This is especially relevant for HIV-positive HNC patients
for whom epidemiologic data suggest high rates of HPV-related
disease.
The strengths of this study are that it is a single institution
experience over 10 years entirely in the HAART era with a con-
sistent curative treatment approach. All patients were treated by
the same two radiation oncologists. Limitations include retro-
spective analysis, which subjects this study to the typical biases,
including selection bias. Additionally, as a retrospective study,
it relies on the accuracy of follow-up clinic notes and imaging
study reports for tabulation of toxicity and the classification of
clinical endpoints. However, given the relative rarity of HNC in
HIV-positive patients, prospective studies may not be feasible.
Additionally, while this represents one of the largest series describ-
ing disease-related outcomes in this setting, patient numbers are
small.
Finally, despite including 24 patients treated over the course of
10 years, median follow-up is only 21 months. This discordance
between duration of the study period and median follow-up is
a limitation of the study. A major contributor to the lack of
follow-up is a large proportion of patients being referred from
a hospital that serves uninsured patients of likely lower socioe-
conomic backgrounds who are less likely to complete routine
follow-up as scheduled. Furthermore, lower rates of retention
in the medical care system for HIV-positive patients have been
documented and are associated with a lack of medical insurance,
lower socioeconomic status, and competing psychosocial needs
(25). Loss to follow-up for HIV specialty care is directly associated
with increased mortality including death from malignancies (26).
Those retained in the care of an infectious disease specialist have
frequent follow-up with many health-care practitioners to man-
age HAART therapy and their other medical co-morbidities. This
can lead to the misperception that sub-specialty follow-up is not
required, which has been recently shown for missed gynecologic
referrals in the setting of abnormal pap tests (27). This study high-
lights the challenge of establishing reliable follow-up with medical
oncology, radiation oncology, and otolaryngology in this patient
population, for whom other social issues may interfere with and
take precedence over cancer surveillance.
CONCLUSION
In this cohort of HIV-positive patients with HNC, RT and CRT
were well-tolerated and resulted in survival and disease control
rates that compare favorably with historical controls. This group
of patients should be managed aggressively with intention to
cure. Despite excellent OS, most patient deaths that did occur
were a result of disease progression. Premature de-escalation of
therapy in this population may result in excess disease-related
deaths.
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